Plaque Biology: Interesting Science or Pharmacological Treasure Trove?

European Journal of Vascular and Endovascular Surgery

Volumn 36, Issue 5, 2008, Pages 507-516

  Loftus, I ^a   Thompson, M ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Atherosclerosis; Biomarkers; Matrix metalloproteinases; Plaque instability; Thrombomodulation

Indexed keywords

ANTHRACYCLINE; BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GELATINASE B; HEPARIN; HOMOCYSTEINE; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN; MACROPHAGE INFLAMMATORY PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN; STEROID; SYNTHETIC PEPTIDE; TETRACYCLINE; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ARTERIAL WALL THICKNESS; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CHLAMYDOPHILA PNEUMONIAE; CYTOMEGALOVIRUS; DISEASE COURSE; HELICOBACTER PYLORI; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD COAGULATION; C-REACTIVE PROTEIN; CARDIOVASCULAR AGENTS; CYTOKINES; DISEASE PROGRESSION; HEMATOLOGIC AGENTS; HOMOCYSTEINE; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPID METABOLISM; MATRIX METALLOPROTEINASES; PROTEASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 53449094972     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2008.06.002     Document Type: Review

References (68)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
2. Buja L.M., and Willerson J.T. Role of inflammation in coronary plaque disruption. Circulation 89 (1994) 503-505
3. Suckling K.E. The vulnerable atherosclerotic plaque. Emerging Drugs 3 (1998) 121-134
4. Pauriah M., Struthers A.D., and Lang C.C. Biomarkers and surrogate endpoints in cardiovascular therapeutics research: under scrutiny following results of the ENHANCE study. Cardiovasc Ther 26 (2008) 85-88
5. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69 (2001) 89-95
6. Davies M.J., Richardson P.D., Woolf N., Katz D.R., and Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extra cellular lipid, macrophage, and smooth muscle cell content. Br Heart J 69 (1993) 377-381
7. Loftus I.M., Naylor A.R., Goodall S., Crowther M., Jones L., Bell P.R.F., et al. Increased MMP-9 activity in unstable carotid plaques- a potential role in acute plaque disruption. Stroke 31 (2000) 40-47
8. van der Wal A.C., Becker A.E., van der Loos C.M., and Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89 (1994) 36-44
9. Cheng G.C., Loree H.M., Kamm R.D., Fishbein M.C., and Lee R.T. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions. A structural analysis with histopathological correlation. Circulation 87 (1993) 1179-1187
10. MacIsaac A.I., Thomas J.D., and Topol E.J. Toward the quiescent coronary plaque. J Am Coll Cardiol 22 (1993) 1228-1241
11. Tofler G.H., Stone P.H., Maclure M., et al. Analysis of possible triggers of acute myocardial infarction (the MILIS study). Am J Cardiol 66 (1990) 22-27
12. Rabbani R., and Topol E.J. Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res 41 (1999) 402-417
13. Ikonomidis I., Stamatelopoulos K., Lekakis J., Vamvakou G.D., and Kremastinos D.T. Inflammatory and non invasive vascular markers: the multi marker approach for risk stratification in coronary artery disease. Atherosclerosis (2008 Feb 29) [Epub ahead of print]
14. Falk E., Shah P.K., and Fuster V. Coronary plaque disruption. Circulation 92 (1995) 657-671
15. Molloy K., and Loftus I.M. Mechanisms of plaque rupture. In: Fitridge R., and Thompson M. (Eds). Mechanisms of vascular disease (2007), Cambridge University Press 103-126
16. Barua R.S., Ambrose J.A., Srivastava S., DeVoe M.C., and Eales-Reynolds L.J. Reactive oxygen species are involved in smoking induced dysfunction of nitric oxide biosynthesis and up regulation of endothelial nitric oxide synthase: an in vitro demonstration in human coronary artery endothelial cells. Circulation 107 (2003) 2342-2347
17. Kolodgie F.D., Burke A.P., Farb A., Gold H.K., Yuan J., Narula J., et al. The thin-cap fibroatheroma: the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol 16 (2001) 285-292
18. Koenig W., and Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 27 (2007) 15-26
19. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (CARE) investigators. Circulation 98 (1998) 839-844
20. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
21. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
22. Alvarez Garcia B., Ruiz C., Chacon P., Sabin J.A., and Matas M. High sensitivity CRP in high grade carotid stenosis: risk marker for unstable carotid plaque. J Vasc Surg 38 (2003) 1018-1024
23. Di Napoli M., Papa F., and Bocola V. CRP in ischaemic stroke. Stroke 32 (2001) 917
24. Haverkate F., Thompson S.G., Pyke S.D., Gallimore J.R., and Pepys M.B. Production of CRP and risk of coronary events in stable and unstable angina. Lancet 349 (1997) 462-466
25. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Plasma concentration of CRP and risk of developing peripheral vascular disease. Circulation 97 (1998) 425-428
26. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
27. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high risk individuals: a randomised placebo controlled trial. Lancet 360 (2002) 7-22
28. Ridker P.M., Rifai N., Clearfield M., Downs J.R., Weis S.E., Miles J.S., et al. Measurement of CRP for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965
29. Ridker P.M., Rifai N., and Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103 (2001) 1191-1193
30. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95 (1998) 8880-8885
31. Shovman O., Levy Y., Gilburd B., and Shoenfeld Y. Anti-inflammatory and immunomodulatory properties of statins. Immunol Res 25 (2002) 271-285
32. Selzman C.H. Mechanistic approaches to therapy for vascular injury. In: Clark L.V. (Ed). Trends in atherosclerosis research (2004), Nova Science Publications 1-34
33. Selzman C.H., Shames B.D., Miller S.A., Pulido E.J., Meng X., Mcintyre Jr. R.C., et al. Therapeutic implications of IL-10 in surgical disease. Shock 10 (1998) 309-318
34. Rosenson R.S., and Tangney C.C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. J Am Med Assoc 279 (1998) 1643-1650
35. Galis Z.S., Asanuma K., Godin D., and Meng X. N-Acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy. Circulation 97 (1998) 2445-2453
36. Ferns G.A., Forster L., Stewart-Lee A., et al. Probucol inhibits neointimal thickening and macrophage accumulation after balloon injury in the cholesterol-fed rabbit. Proc Natl Acad Sci USA 89 (1992) 11312-11316
37. Rimm E.B., Stampfer M.J., Ascherio A., et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 328 (1993) 1450-1456
38. Stampfer M.J., Hennekens C.H., Manson J.E., et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 328 (1993) 1444-1449
39. Stephens N.G., Parsons A., Schofield P.M., et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347 (1996) 781-786
40. Rapola J.M., Virtamo J., Ripatti S., et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infraction. Lancet 349 (1997) 1715-1720
41. Levonen A.L., Vahakangas E., Koponen J.K., and Yla-Herttuala S. Antioxidant gene therapy for cardiovascular disease: current status and future perspectives. Circulation 117 (2008) 2142-2150
42. Tardif J.C., Grégoire J., L'Allier P.L., Ibrahim R., Lespérance J., Heinonen T.M., et al., Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297 (2007) 1675-1682
43. Brewer Jr. H.B. HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease. Curr Cardiol Rep 9 (2007) 486-492
44. Welch G.N., and Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 338 (1998) 1042-1050
45. Lin C.P., Chen Y.H., Lin W.T., Leu H.B., Liu T.Z., Huang S.L., et al. Direct effect of statins on homocysteine-induced endothelial adhesiveness: potential impact to human atherosclerosis. Eur J Clin Invest 38 (2008) 106-116
46. Muhlestein J.B., Anderson J.L., Hammond E.H., Zhao L., Trehan S., Schwobe E.P., et al. Infection with Chlamydia pneumoniae accelerates the development of atheroscerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 97 (1998) 633-636
47. Ossei-Gerning N., Moayyedi P., Smith S., Braunholtz D., Wilson J.I., Axon A.T., et al. Helicobacter pylori infection is related to atheroma in patients undergoing coronary angiography. Cardiovasc Res 35 (1997) 120-124
48. Nieto F.J., Adam E., Sorlie P., Farzadegan H., Melnick J.L., Comstock G.W., et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of sub clinical atherosclerosis. Circulation 94 (1996) 922-927
49. Kaukoranta-Tolvanen S.S., Ronni T., Leinonen M., Saikku P., and Laitinen K. Expression of adhesion molecules on endothelial cells stimulated by Chlamydia pneumoniae. Microb Pathog 21 (1996) 407-411
50. Heinemann M., Susa M., Simnacher U., Marre R., and Essig A. Growth of Chlamydia pneumoniae induces cytokine production and expression of CD14 in a human monocytic cell line. Infect Immun 64 (1996) 4872-4875
51. Kol A., Sukhova G.K., Lichtman A.H., and Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-α and matrix metalloproteinase expression. Circulation 98 (1998) 300-307
52. Stone A.F., Mendall M.A., Kaski J.C., Edger T.M., Risley P., Poloniecki J., et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 106 (2002) 1219-1223
53. O'Connor C.M., Dunne M.W., Pfeffer M.A., Muhlestein J.B., Yao L., Gupta S., et al., Investigators in the WIZARD Study. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 290 (2003) 1459-1466
54. Shah P.K., Falk E., Badimon J.J., Fernandez-Ortiz A., Mailhac A., Villareal-Levy G., et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 92 (1995) 1565-1569
55. Loftus I.M., Naylor A.R., Bell P.R.F., and Thompson M.M. MMPs and atherosclerotic plaque instability. Br J Surg 89 (2002) 680-694
56. Dollery C.M., McEwan J.R., and Henney A.M. Matrix metalloproteinases and cardiovascular disease. Circ Res 77 (1995) 863-868
57. Mauviel A. Cytokine regulation of metalloproteinase gene expression. J Cell Biochem 53 (1993) 288-295
58. Gogly B., Hornebeck W., Groult N., Godeau G., and Pellat B. Influence of heparin(s) on the interleukin-1β-induced expression of collagenase, stromelysin-1, and tissue inhibitor of metalloproteinase-1 in human gingival fibroblasts. Biochem Pharmacol 56 (1998) 1447-1454
59. Lijnen H.R. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 86 (2001) 324-333
60. Gomez D.E., Alonso D.F., Yoshiji H., and Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74 (1997) 111-122
61. Axisa B., Loftus I.M., Naylor A.R., Goodall S., Jones L., Bell P.R.F., et al. A prospective randomised double blinded trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 33 (2002) 2858-2864
62. Baxter B.T., Pearce W.H., Waltke E.A., Littooy F.N., Hallett Jr. J.W., Kent K.C., et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicentre study. J Vasc Surg 36 (2002) 1-12
63. Jander S., Sitzer M., Wendt A., Schroeter M., Buchkremer M., Siebler M., et al. Expression of tissue factor in high-grade carotid artery stenosis: association with plaque destabilization. Stroke 32 (2001) 850-854
64. Penn M.S., and Topol E.J. Tissue factor, the emerging link between inflammation, thrombosis and vascular remodelling. Circ Res 89 (2001) 1-2
65. Moreno P.R., Bernardi V.H., López-Cuéllar J., Murcia A.M., Palacios I.F., Gold H.K., et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 94 (1996) 3090-3097
66. Crawley J.T., and Lane D.A. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 28 (2008) 233-242
67. Steins M.B., Padró T., Li C.X., Mesters R.M., Ostermann H., Hammel D., et al. Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries. Atherosclerosis 145 (1999) 173-180
68. Padró T., Steins M., Li C.X., Mesters R.M., Hammel D., Scheld H.H., et al. Comparative analysis of plasminogen activator inhibitor-1 expression in different types of atherosclerotic lesions in coronary arteries from human heart explants. Cardiovasc Res 36 (1997) 28-36